PRGO - OTC Medicine Player Perrigo Outlines Three-Year Cost Saving Plan Posts Mixed Q4 Earnings | Benzinga
Perrigo Company plc (NYSE:PRGO) reported fourth-quarter 2023 net sales of $1.16 billion, up 0.1% Y/Y, slightly below the consensus of $1.18 billion.
Organic net sales decreased by 0.6%, including a -2.4 percentage points impact from purposeful SKU prioritization actions to enhance margins as part of the company’s Supply Chain Reinvention Program and the final quarter of HRA Pharma distributor transitions.
Organic net sales included strategic pricing actions of +3.9 percentage points and volume/mix of -4.2 percentage points.
Consumer Self-Care America net sales of $744 million decreased 2.8%, including -1.4 percentage points from exited product lines, partially offset ...